[Skip to Content]
Clinical Pharmacy and Pharmacology

Remdesivir and Dexamethasone for the Treatment of COVID-19

JAMA
Published Online: July 20, 2020 Audio Clinical Review 36 min 28 sec
<title>Remdesivir and Dexamethasone for the Treatment of COVID-19</title>
Backward 15 Play Pause Forward 15
1x
0:00 / 0:00
Download MP3

Both remdesivir and dexamethasone have been promoted as effective treatments for COVID-19. JAMA Deputy Editor Greg Curfman, MD, and Professor Rachel Sachs, JD, from the Washington University School of Law discuss the science and health policy aspects of these COVID-19 treatments.

Subscribe

Subscribe on your favorite podcast source to receive future episodes of this podcast.
Learn more about this JAMA Network podcast here

Related Articles

  1. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

  2. Emergency Use Authorization of Remdesivir

  3. A Proposed Lottery System to Allocate Scarce COVID-19 Medications

  4. Missed Opportunities in the FDA’s Emergency Use Authorization of Remdesivir

See More

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

See More About

Clinical Pharmacy and Pharmacology Drug Development Regulatory Agencies Ethics Health Policy Coronavirus (COVID-19) Law and Medicine Health Care Economics, Insurance, Payment Infectious Diseases Pharmacoeconomics
Close
Close

Name Your Search

Save Search
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue